Current Report Filing (8-k)
June 17 2021 - 2:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): June 15, 2021
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
001-35141
|
|
68-0370244
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
931
Village Boulevard, Suite 905, West Palm Beach,
Florida
|
|
33409
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(561)
855-1626
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered under Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
June 15, 2021, Seamus Lagan, Chief Executive Officer, President and Interim Chief Financial Officer of Rennova Health, Inc. (the “Company”),
and Alcimede LLC, of which Mr. Lagan is the sole manager, the holders of 250,000 shares of Series L Convertible Preferred Stock and an irrevocable proxy to vote all of the outstanding shares of Series M Convertible Redeemable Preferred Stock, each of which
votes with the common stock and Series F Convertible Preferred Stock (the “Series F Preferred Stock”), representing approximately
52.6% of the total voting power of the Company’s voting securities, approved by written consent in lieu of a special meeting of
stockholders, the following proposal, which had previously been approved and recommended to be approved by the stockholders by the
Board of Directors of the Company.
Proposal
1: To approve an amendment to our Certificate of Incorporation, as amended to effect a reverse stock split of all of the outstanding
shares of our common stock, at a specific ratio from 1-for-50 to 1-for-2,000, and grant authorization to our Board of Directors to determine,
in its discretion, the specific ratio and timing of the reverse split at any time on or before December 31, 2021, subject to the Board
of Directors’ discretion to abandon such amendment.
The
stockholder approval of the above proposal will not be effective until 20 days after an information statement that has been filed with
the Securities and Exchange Commission is mailed to the holders of our common stock and Series F Preferred Stock.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
June 17, 2021
|
RENNOVA
HEALTH, INC.
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
Seamus
Lagan
|
|
|
Chief
Executive Officer
|
|
|
(principal
executive officer)
|
Rennova Health (CE) (USOTC:RNVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rennova Health (CE) (USOTC:RNVA)
Historical Stock Chart
From Sep 2023 to Sep 2024